1596348-32-1

Basic information

• Product Name: KDM5-C70
• CAS NO: 1596348-32-1
• Molecular Weight: 336.434
• Mol File: 1596348-32-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: KDM5-C70(CAS DataBase Reference)
• NIST Chemistry Reference: KDM5-C70(1596348-32-1)
• EPA Substance Registry System: KDM5-C70(1596348-32-1)

Safety Data

• Hazardous Substances Data: 1596348-32-1(Hazardous Substances Data)

Usage

Uses

KDOAM 21 is an inhibitor to KDM5A (Lysine Demethylase 5A) which is a protein coding gene.

Upstream product

• 41438-38-4 diethyl pyridine-2,4-dicarboxylate 
• 499-80-9 pyridine-2,4-dicarboxylic acid 
• 21908-08-7 ethyl 2-formylpyridine-4-carboxylate 
• 123-83-1 N'-ethyl-N,N-dimethyl-1,2-ethanediamine 

Relevant articles and documents

HISTONE DEMETHYLASE 5 INHIBITORS AND USES THEREOF

Provided herein are compounds of Formulae (I) and (II), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the compounds or compositions disclosed herein for treating and/or preventing proliferative diseases, cancers, carcinoma lung cancer, breast cancer, liver cancer, pancreatic cancer, gastric cancer, ovarian cancer, colon cancer, colorectal cancer, leukemia, sarcoma and/or cardiovascular diseases in a subject in need thereof. In certain embodiments, the sarcoma is Ewing's sarcoma. Provided are methods of inhibiting a histone demethylase in a subject and/or in a cell, tissue, or biological sample. In certain embodiments, the histone demethylase is a KDM. In certain embodiments, the KDM is KDM5. In certain embodiments, the biological sample is a cell. In certain embodiments, the biological sample is a tissue.

INHIBITORS OF HISTONE DEMETHYLASES

Compounds of the form In which Q is selected from -CH=NR12, –W, -CH=2NHR13, –CH=O and -CH(OR17)2 capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer and formulations and methods of use of such compounds.